<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637999</url>
  </required_header>
  <id_info>
    <org_study_id>MYR 201 (HDV)</org_study_id>
    <nct_id>NCT02637999</nct_id>
  </id_info>
  <brief_title>Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection</brief_title>
  <official_title>Randomized Open-label Substudy of Daily Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative Chronic Hepatitis B Co-infected With Hepatitis Delta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepatera Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hepatera Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a
      (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus
      (HBV) co-infected with hepatitis delta virus (HDV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to evaluate safety and efficacy of MXB in a subset of HBV infected
      patients who are co-infected with HDV. Hepatitis delta represents the most severe form of
      chronic viral hepatitis and there is no approved treatment option available for patients
      infected with both HBV and HDV.

      24 patients will be randomised into 3 arms: pre-treatment with MXB followed by PEG-INF-a
      treatment versus a combination of both drugs versus PEG-INF-a.

      Prolonged blockade of HBV entry into hepatocytes should also block infection with HDV
      particles (which uses hepatitis B surface antigen (HBsAg) as its envelope) and thus provide a
      therapeutic option for this otherwise hardly treatable disease. PEG-INF-a is used for the
      treatment of chronic hepatitis delta. The study endpoints are virological response (HBsAg,
      hepatitis delta virus ribonucleic acid (HDV RNA), hepatitis B virus deoxyribonucleic acid
      (HBV DNA)), as well as safety and tolerability and drug immunogenicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2014</start_date>
  <completion_date type="Actual">January 21, 2016</completion_date>
  <primary_completion_date type="Actual">January 21, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 12 of Therapy</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>HBsAg response was defined as serum HBsAg decline of at least 0.5 log IU/mL (or HBsAg negativation) at week 12 compared to baseline (including the patient with negative baseline level)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 24 of Therapy</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>HBsAg response was defined as serum HBsAg decline of at least 0.5 log IU/mL (or HBsAg negativation) at week 24 compared to baseline (including the patient with negative baseline level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 24 of Therapy</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>HBV DNA response was defined as persistent reduction of HBV DNA by &gt; 1 log IU/mL or negativation (including the patient with negative baseline level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 12 of Therapy</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>HBV DNA response was defined as persistent reduction of HBV DNA by &gt; 1 log IU/mL or negativation (including the patient with negative baseline level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 12 of Therapy</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>HDV RNA response was defined as persistent reduction of HDV RNA by &gt; 1 log IU/mL or negativation (including the patient with negative baseline level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 24 of Therapy</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>HDV RNA response was defined as persistent reduction of HDV RNA by &gt; 1 log IU/mL or negativation (including the patient with negative baseline level)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Biochemical Response at Week 12 of Therapy</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Biochemical response was defined as normalization of ALT level as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Biochemical Response at Week 24 of Therapy</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Biochemical response was defined as normalization of ALT level as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Covalently Closed Circular Deoxyribonucleic Acid (cccDNA) Response at Week 72 of Therapy</measure>
    <time_frame>Baseline and 72 weeks for arm A and 48 weeks for arms B and C</time_frame>
    <description>Virological cccDNA response was defined as reduction of intrahepatic cccDNA by 0.5 log in comparison to baseline at the end of follow up.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Chronic Hepatitis D Infection</condition>
  <arm_group>
    <arm_group_label>MXB then PEG IFN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MXB + PEG IFN then PEG IFN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG IFN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG IFN alfa-2a</intervention_name>
    <arm_group_label>MXB then PEG IFN</arm_group_label>
    <arm_group_label>MXB + PEG IFN then PEG IFN</arm_group_label>
    <arm_group_label>PEG IFN</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myrcludex B</intervention_name>
    <arm_group_label>MXB then PEG IFN</arm_group_label>
    <arm_group_label>MXB + PEG IFN then PEG IFN</arm_group_label>
    <other_name>Myrcludex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis B defined by the presence of HBsAg for at least 6 months prior to
             screening period. Co-infection with hepatitis D virus defined as positive anti-HDV
             antibodies for at least 3 months and positive for HDV-RNA within the screening period.

          -  Liver biopsy performed within one year prior to screening or during screening period.

          -  HBeAg negative

          -  All women of childbearing potential must have a negative urine pregnancy test prior to
             enrolment.

          -  Women must:

               1. Be menopausal for at least 2 years, or

               2. Be surgically sterile (total hysterectomy or bilateral ovariectomy or bilateral
                  tubal ligation/clips or otherwise be incapable of pregnancy), or

               3. Not be heterosexually active during the study, or

               4. Agree to use a highly effective method of birth control (double barrier method or
                  combination of barrier method with hormonal or intrauterine device) during the
                  study and for 3 month after the last dosing of the investigational medicinal
                  product.

          -  Men must agree to use a highly effective method of birth control (double barrier
             methods or combination of barrier method with hormonal or intrauterine device in their
             women-partner) and not to donate a sperm during the study and for 3 month after the
             last dosing of the investigational medicinal product.

          -  An understanding, ability and willingness to fully comply with study procedures and
             restrictions.

          -  An ability to provide the written informed consent to participate in the study

        Exclusion Criteria:

          -  Decompensated liver disease (Child-Pugh-Score &gt;6).

          -  Co-infected with hepatitis C virus (HCV), or HIV.

          -  Patients with presence of anti-HCV antibody and negative HCV RNA in two separate
             occasions within 12 months prior to screening could be enrolled into the study after
             sponsor written permission.

          -  ALT &gt; 6 ULN.

          -  Creatinine clearance &lt; 60 mL/min.

          -  Total bilirubin &gt; 2 mg/dL.

          -  Confirmed contraindication for treatment with PEG-INF-a.

          -  History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC, such
             as suspicious foci on imaging studies or elevated serum alpha-fetoprotein (AFP)
             levels. In patients with such findings, HCC will be ruled-out prior to screening for
             the present study.

          -  One or more additional known primary or secondary causes of liver disease, other than
             hepatitis B (e.g., alcoholism, autoimmune hepatitis, malignancy with hepatic
             involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's Disease, other
             congenital or metabolic conditions affecting the liver, e.g. congestive heart failure
             or other severe cardiopulmonary disease). Patients with Gilbert's syndrome and
             Dubin-Johnson syndrome, two benign disorders associated with low-grade
             hyperbilirubinemia can be enrolled into the trial.

          -  History of clinically evident pancreatitis.

          -  History of alcohol or drug abuse within the preceding two years. For the purposes of
             the present study, alcohol abuse is arbitrarily defined as frequent consumption of
             alcoholic beverages with an average daily intake of more than 40 g of ethanol.

          -  Participation in another study with an investigational drug within less than one month
             prior to this study or simultaneously to this study.

          -  Patients who are unable or unwilling to follow the protocol requirements.

          -  Patients with a history of seizures, central nervous system disorders or psychiatric
             disability thought to be clinically significant in the opinion of the investigator.

          -  Patients with limited mental capacity to the extent that she/he cannot provide
             informed consent or information regarding adverse events of the study drug.

          -  Clinically significant renal, respiratory or cardiovascular disease.

          -  Pregnancy and lactation.

          -  Patients who have previously participated in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel Bogomolov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LLC &quot;Clinical Hospital of Tsentrosoyuz&quot;</affiliation>
  </overall_official>
  <reference>
    <citation>Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004 Mar;11(2):97-107. Review.</citation>
    <PMID>14996343</PMID>
  </reference>
  <reference>
    <citation>Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012 Nov 13;1:e00049. doi: 10.7554/eLife.00049. Erratum in: Elife. 2014;3:e05570.</citation>
    <PMID>23150796</PMID>
  </reference>
  <reference>
    <citation>Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003 Apr;83(2):633-71. Review.</citation>
    <PMID>12663868</PMID>
  </reference>
  <reference>
    <citation>Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009 May;136(5):1629-38. doi: 10.1053/j.gastro.2009.01.052. Epub 2009 Jan 29.</citation>
    <PMID>19208358</PMID>
  </reference>
  <reference>
    <citation>Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Schirmacher P, Fleig WE, Manns MP. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol. 2007 Dec;45(12):1281-328.</citation>
    <PMID>18080231</PMID>
  </reference>
  <reference>
    <citation>Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol. 2016 Sep;65(3):483-9. doi: 10.1016/j.jhep.2016.04.013. Epub 2016 Apr 27.</citation>
    <PMID>27132172</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <results_first_submitted>December 28, 2017</results_first_submitted>
  <results_first_submitted_qc>April 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2018</results_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
    <mesh_term>Hepatitis D, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MXB Then PEG IFN</title>
          <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>MXB + PEG IFN Then PEG IFN</title>
          <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks</description>
        </group>
        <group group_id="P3">
          <title>PEG IFN</title>
          <description>PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MXB Then PEG IFN</title>
          <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>MXB + PEG IFN Then PEG IFN</title>
          <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>PEG IFN</title>
          <description>PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="10.05"/>
                    <measurement group_id="B2" value="33.0" spread="4.87"/>
                    <measurement group_id="B3" value="42.1" spread="10.23"/>
                    <measurement group_id="B4" value="37.8" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 12 of Therapy</title>
        <description>HBsAg response was defined as serum HBsAg decline of at least 0.5 log IU/mL (or HBsAg negativation) at week 12 compared to baseline (including the patient with negative baseline level)</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>MXB Then PEG IFN</title>
            <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>MXB + PEG IFN Then PEG IFN</title>
            <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks, followed by pegINF 180mcg once weekly for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>PEG IFN</title>
            <description>PEG IFN alfa-2a, 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 12 of Therapy</title>
          <description>HBsAg response was defined as serum HBsAg decline of at least 0.5 log IU/mL (or HBsAg negativation) at week 12 compared to baseline (including the patient with negative baseline level)</description>
          <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 24 of Therapy</title>
        <description>HBsAg response was defined as serum HBsAg decline of at least 0.5 log IU/mL (or HBsAg negativation) at week 24 compared to baseline (including the patient with negative baseline level)</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>MXB Then PEG IFN</title>
            <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>MXB + PEG IFN Then PEG IFN</title>
            <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks, followed by pegINF 180mcg once weekly for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>PEG IFN</title>
            <description>PEG IFN alfa-2a, 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 24 of Therapy</title>
          <description>HBsAg response was defined as serum HBsAg decline of at least 0.5 log IU/mL (or HBsAg negativation) at week 24 compared to baseline (including the patient with negative baseline level)</description>
          <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 24 of Therapy</title>
        <description>HBV DNA response was defined as persistent reduction of HBV DNA by &gt; 1 log IU/mL or negativation (including the patient with negative baseline level)</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MXB Then PEG IFN</title>
            <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>MXB + PEG IFN Then PEG IFN</title>
            <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks, followed by pegINF 180mcg once weekly for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>PEG IFN</title>
            <description>PEG IFN alfa-2a, 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 24 of Therapy</title>
          <description>HBV DNA response was defined as persistent reduction of HBV DNA by &gt; 1 log IU/mL or negativation (including the patient with negative baseline level)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 12 of Therapy</title>
        <description>HBV DNA response was defined as persistent reduction of HBV DNA by &gt; 1 log IU/mL or negativation (including the patient with negative baseline level)</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>MXB Then PEG IFN</title>
            <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>MXB + PEG IFN Then PEG IFN</title>
            <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks, followed by pegINF 180mcg once weekly for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>PEG IFN</title>
            <description>PEG IFN alfa-2a, 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 12 of Therapy</title>
          <description>HBV DNA response was defined as persistent reduction of HBV DNA by &gt; 1 log IU/mL or negativation (including the patient with negative baseline level)</description>
          <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 12 of Therapy</title>
        <description>HDV RNA response was defined as persistent reduction of HDV RNA by &gt; 1 log IU/mL or negativation (including the patient with negative baseline level)</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>MXB Then PEG IFN</title>
            <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>MXB + PEG IFN Then PEG IFN</title>
            <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks, followed by pegINF 180mcg once weekly for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>PEG IFN</title>
            <description>PEG IFN alfa-2a, 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 12 of Therapy</title>
          <description>HDV RNA response was defined as persistent reduction of HDV RNA by &gt; 1 log IU/mL or negativation (including the patient with negative baseline level)</description>
          <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 24 of Therapy</title>
        <description>HDV RNA response was defined as persistent reduction of HDV RNA by &gt; 1 log IU/mL or negativation (including the patient with negative baseline level)</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>MXB Then PEG IFN</title>
            <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>MXB + PEG IFN Then PEG IFN</title>
            <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks, followed by pegINF 180mcg once weekly for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>PEG IFN</title>
            <description>PEG IFN alfa-2a, 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 24 of Therapy</title>
          <description>HDV RNA response was defined as persistent reduction of HDV RNA by &gt; 1 log IU/mL or negativation (including the patient with negative baseline level)</description>
          <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Biochemical Response at Week 12 of Therapy</title>
        <description>Biochemical response was defined as normalization of ALT level as compared to baseline.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>MXB Then PEG IFN</title>
            <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>MXB + PEG IFN Then PEG IFN</title>
            <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks, followed by pegINF 180mcg once weekly for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>PEG IFN</title>
            <description>PEG IFN alfa-2a, 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Biochemical Response at Week 12 of Therapy</title>
          <description>Biochemical response was defined as normalization of ALT level as compared to baseline.</description>
          <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Biochemical Response at Week 24 of Therapy</title>
        <description>Biochemical response was defined as normalization of ALT level as compared to baseline.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>MXB Then PEG IFN</title>
            <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>MXB + PEG IFN Then PEG IFN</title>
            <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks, followed by pegINF 180mcg once weekly for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>PEG IFN</title>
            <description>PEG IFN alfa-2a, 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Biochemical Response at Week 24 of Therapy</title>
          <description>Biochemical response was defined as normalization of ALT level as compared to baseline.</description>
          <population>For the efficacy assessments the main analysis set was Full analysis set (FAS): All patients of the Safety set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Covalently Closed Circular Deoxyribonucleic Acid (cccDNA) Response at Week 72 of Therapy</title>
        <description>Virological cccDNA response was defined as reduction of intrahepatic cccDNA by 0.5 log in comparison to baseline at the end of follow up.</description>
        <time_frame>Baseline and 72 weeks for arm A and 48 weeks for arms B and C</time_frame>
        <population>No data to be reported due to absence of biopsy data. Biopsy data are unavailable because analyses were not performed</population>
        <group_list>
          <group group_id="O1">
            <title>MXB Then PEG IFN</title>
            <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>MXB + PEG IFN Then PEG IFN</title>
            <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks, followed by pegINF 180mcg once weekly for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>PEG IFN</title>
            <description>PEG IFN alfa-2a, 180 µg/0.5 mL once weekly for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Covalently Closed Circular Deoxyribonucleic Acid (cccDNA) Response at Week 72 of Therapy</title>
          <description>Virological cccDNA response was defined as reduction of intrahepatic cccDNA by 0.5 log in comparison to baseline at the end of follow up.</description>
          <population>No data to be reported due to absence of biopsy data. Biopsy data are unavailable because analyses were not performed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MXB Then PEG IFN</title>
          <description>Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>MXB + PEG IFN Then PEG IFN</title>
          <description>Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 24 weeks, followed by pegINF 180mcg once weekly for 24 weeks</description>
        </group>
        <group group_id="E3">
          <title>PEG IFN</title>
          <description>PEG IFN alfa-2a, 180 µg/0.5 mL once weekly for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E3" events="17" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="15" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E3" events="21" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="14" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" events="20" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gama-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>APTT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. med. Alexander Alexandrov</name_or_title>
      <organization>MYR GmbH</organization>
      <phone>+491777168259</phone>
      <email>alexandrov@myr-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

